{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalComment":"P-value from Analysis of Variance with main effects (treatment and age group) model after testing for non-significant interaction (p-value ≥ 0.10).","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"22","value":"1.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"24","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Number of weeks with platelet counts ≥ 50 x 10\\^9/L during week 2 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.","dispersionType":"Full Range","groups":[{"description":"Participants received weekly subcutaneous placebo for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\\^9/L.","id":"OG001","title":"Romiplostim"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"Week 2 to week 25","title":"Number of Weeks With Platelet Response","type":"SECONDARY","unitOfMeasure":"weeks"}